ANDA 211647, held by Alkem Laboratories. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 211647 (Methylphenidate Hydrochloride), held by Alkem Laboratories, was first approved by FDA on Mar 30, 2020, with 1 approved supplement and 0 published complete response letters.
Methylphenidate hydrochloride oral solution is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years of age and older Narcolepsy
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 30, 2020 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride5MG/5ML · solution;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride10MG/5ML · solution;oral | Methylphenidate Hydrochloride | Rx |
| Jan 29, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 30, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters